MESO241220C13000
- 0.65
- +0.40+160.00%
Mesoblast Newsroom
Stocks Making Moves On Friday: CRDO, MRVL And CIEN
RFK Jr. Could Prove a Surprise Boon for Stem-cell Stocks With Pivotal Year Ahead
Stem Cells Poised for Success in 2025 as Regulatory Environment Looks More Favorable -- Market Talk
Promising Developments and Regulatory Catalysts Highlight Mesoblast's Growth Potential
Sector Update: Health Care Stocks Mixed Premarket Thursday
SentinelOne, AeroVironment, PVH And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Anticipated Jobs Reports
Mesoblast Secures Regenerative Advanced Therapy Designation From US FDA for Cellular Therapy Product; Shares Hit Near 3.5-Year High
FDA Grants Mesoblast's Revascor Regenerative Medicine Advanced Therapy Designation In Children With Congenital Heart Disease
Mesoblast's Cell Therapy Shows Improved Outcomes in Heart Disease Patients in Phase 3 Study
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
Mesoblast Limited's (ASX:MSB) 17% Gain Last Week Benefited Both Retail Investors Who Own 54% as Well as Insiders
JPMorgan Chase Takes Significant Stake in Mesoblast
Mesoblast Announces Director Change and Shareholdings
Mesoblast Limited's AGM Resolutions Gain Strong Approval
Mesoblast Director Joseph Swedish Steps Down
Mesoblast Limited Outlines Future Strategies and Growth Prospects
Mesoblast Limited Issues Unquoted Warrants in Strategic Move
Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $18
Buy Rating for Mesoblast Driven by Promising Market Opportunities and Upcoming PDUFA Date for Ryoncil